Toshio Hattori

Prof. Toshio Hattori

Kibi International University
orcid
Visiting Prof. Shizuoka Graduate University of Public Health

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2007 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
YIYuuki Inoue
Yuuki Inoue
NTNobuyuki Tanaka
Nobuyuki Tanaka
YTYoshinori Tanaka
Yoshinori Tanaka
SIShingo Inoue
Shingo Inoue
KMKouichi Morita
Kouichi Morita
KSKazuo Sugamura
Kazuo Sugamura
The penetration of various viruses into host cells is accomplished by hijacking the host endocytosis machinery. In the case of severe acute respiratory syndrome coronavirus (SARS-CoV) infection, viral entry is reported to require a low pH in intracytoplasmic vesicles; however, little is known about how SARS-CoV invades such compartments. Here we demonstrate that SARS-CoV mainly utilizes the clathrin-mediated endocytosis pathway for its entry to target cells by using infectious SARS-CoV, as well as a SARS-CoV pseudovirus packaged in the SARS-CoV envelope. The SARS-CoV entered caveolin-1-negative HepG2 cells, and the entry was significantly inhibited by treatment with chlorpromazine, an inhibitor for clathrin-dependent endocytosis, and by small interfering RNA-mediated gene silencing for the clathrin heavy chain. Furthermore, the SARS-CoV entered COS7 cells transfected with the mutant of ACE2 with the cytoplasmic tail deleted, SARS-CoV receptor, as well as the wild-type ACE2, and their entries were significantly inhibited by treatment with chlorpromazine. In addition, ACE2 translocated into EEA1-positive early endosomes immediately after the virus attachment to ACE2. These results suggest that when SARS-CoV binds ACE2 it is internalized and penetrates early endosomes in a clathrin-dependent manner and that the cytoplasmic tail of ACE2 is not required for the penetration of SARS-CoV.

1 December 1998 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HTHirokazu Tamamura
Hirokazu Tamamura
YXYounong Xu
Younong Xu
Toshio HattoriToshio Hattori
Toshio Hattori
XZXiaoyan Zhang
Xiaoyan Zhang
RARieko Arakaki
Rieko Arakaki
NFNobutaka Fujii
Nobutaka Fujii

1 March 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TKTomomi Kitamuro
Tomomi Kitamuro
KTKazuhiro Takahashi
Kazuhiro Takahashi
KOKazuhiro Ogawa
Kazuhiro Ogawa
RUReiko Udono-Fujimori
Reiko Udono-Fujimori
KTKazuhisa Takeda
Kazuhisa Takeda
SSShigeki Shibahara
Shigeki Shibahara
Heme oxygenase 1 (HO-1) catalyzes heme breakdown, eventually releasing iron, carbon monoxide, and bilirubin IXα. HO-1 is induced by its substrate heme and various environmental factors, which represents a protective response against oxidative stresses. Here we show that hypoxia represses HO-1 expression in three human cell types but induces it in rat, bovine, and monkey cells, indicating the inter-species difference in the hypoxic regulation of HO-1 expression. The hypoxia-mediated repression of HO-1 expression is consistently associated with the induction of Bach1, a heme-regulated transcriptional repressor, in human cells. Bach1 is a basic leucine zipper protein, forming a heterodimer with a small Maf protein. Expression of HO-1 was also reduced in human cells when exposed to interferon-γ or an iron chelator desferrioxamine, each of which induced Bach1 expression. In contrast, induction of HO-1 expression by CoCl2 is associated with reduced expression of Bach1 mRNA. Thus, expression of HO-1 and Bach1 is inversely regulated. We have identified a Maf recognition element in the human HO-1gene that is required for repression of a reporter gene by hypoxia and targeted by Bach1. Therefore, Bach1 functions as a hypoxia-inducible repressor for the HO-1 gene, thereby contributing to fine-tuning of oxygen homeostasis in human cells.

1 June 1988 in Journal of Virology
Verified
Journal Article
Closed access
SMS Matsushita
S Matsushita
MRM Robert-Guroff
M Robert-Guroff
JRJ Rusche
J Rusche
AKA Koito
A Koito
Toshio HattoriToshio Hattori
Toshio Hattori
SPS Putney
S Putney
A monoclonal antibody was produced to the exterior envelope glycoprotein (gp120) of the human T-cell lymphotropic virus (HTLV)-IIIB isolate of the human immunodeficiency virus (HIV). This antibody binds to gp120 of HTLV-IIIB and lymphadenopathy-associated virus type 1 (LAV-1) and to the surface of HTLV-IIIB- and LAV-1-infected cells, neutralizes infection by cell-free virus, and prevents fusion of virus-infected cells. In contrast, it does not bind, or weakly binds, the envelope of four heterologous HIV isolates and does not neutralize heterologous isolates HTLV-IIIRF and HTLV-IIIMN. The antibody-binding site was mapped to a 24-amino-acid segment, using recombinant and synthetic segments of HTLV-IIIB gp120. This site is within a segment of amino acid variability known to contain the major neutralizing epitopes (S. D. Putney, T. J. Matthews, W. G. Robey, D. L. Lynn, M. Robert-Guroff, W. T. Mueller, A. J. Langlois, J. Ghrayeb, S. R. Petteway, K. J. Weinhold, P. J. Fischinger, F. Wong-Staal, R. C. Gallo, and D. P. Bolognesi, Science 234:1392-1395, 1986). These results localize an epitope of HIV type-specific neutralization and suggest that neutralizing antibodies may be effective in controlling cell-associated, as well as cell-free, virus infection.

1 January 1981
Verified
Journal Article
Closed access
Toshio HattoriToshio Hattori
Toshio Hattori
TUT Uchiyama
T Uchiyama
TTT Toibana
T Toibana
KTK Takatsuki
K Takatsuki
HUH Uchino
H Uchino

1 April 2009 in Antiviral Research
Verified
Journal Article
Closed access
MZMin Zhuang
Min Zhuang
HJHong Jiang
Hong Jiang
YSYasuhiro Suzuki
Yasuhiro Suzuki
XLXiaoguang Li
Xiaoguang Li
PXPeng Xiao
Peng Xiao
Toshio HattoriToshio Hattori
Toshio Hattori